Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients

Transplantation
Andreas O DoeschThomas Dengler

Abstract

Graft denervation in heart transplant recipients causes sinus tachycardia, occasionally requiring pharmacologic heart rate reduction. Currently, no 12-month data regarding effects of the novel I(f) channel antagonist ivabradine on heart rate control, effects on left ventricular mass, tolerability, and safety are available in patients after heart transplantation (HTX). Mean heart rate, left ventricular mass indexed (LVMI) to body surface area, tolerability, and safety of ivabradine therapy were evaluated at baseline and after 12 months in 30 HTX recipients with marked sinus tachycardia. In three patients (10.0% of total), ivabradine medication was discontinued. Further analysis was based on 27 patients with 12-month drug exposure. Mean patient age was 53.3+/-11.3 years, and mean time after HTX was 5.0+/-4.8 years. Mean ivabradine dose was 12.5 mg/day (+/-3.3 mg). Mean heart rate was reduced from 96.2+/-8.6 beats per minute (bpm) at baseline to 80.9+/-8.1 bpm at follow-up (P<0.0001). A statistically significant effect of heart rate reduction on LVMI was observed (104.3+/-22.7 g at baseline vs. 95.9+/-18.5 g at follow-up, P=0.04). No statistically significant changes in immunosuppressive drug dosage or blood levels were observed, ...Continue Reading

References

Feb 15, 1986·The American Journal of Cardiology·R B DevereuxN Reichek
Oct 8, 1997·Journal of the American College of Cardiology·H J Levine
Apr 20, 1999·Circulation·X JouvenP Ducimetière
Oct 11, 2005·European Heart Journal·Jean-Claude TardifUNKNOWN INITIATIVE Investigators
Dec 21, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Feras M BaderEdward M Gilbert
Jul 24, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·R ZhangChristoph Bara

❮ Previous
Next ❯

Citations

Mar 7, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Ruoyu ZhangChristoph Bara
Apr 27, 2010·Advances in Therapy·Graziano Riccioni
Oct 20, 2012·Cardiovascular Research·Manoraj NavaratnarajahCesare M Terracciano
Oct 30, 2012·Transplantation·William R CritchleyJames E Fildes
Jan 25, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Benjamin LauzierChristine Des Rosiers
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Neeraj Parakh, Balram Bhargava
Sep 14, 2012·Heart Failure Reviews·Maya Guglin
Jan 13, 2015·International Journal of Molecular Sciences·Stefan HerrmannAndreas Ludwig
Jan 23, 2016·Current Heart Failure Reports·Gabriela OrasanuGuilherme H Oliveira
Feb 3, 2016·Current Treatment Options in Cardiovascular Medicine·Takeshi Kitai, W H Wilson Tang
Oct 26, 2010·Transplantation Proceedings·E Lage-GalléA Martínez-Martínez
Mar 16, 2013·Transplant International : Official Journal of the European Society for Organ Transplantation·Josep L Melero-FerrerAntonio Salvador-Sanz
Aug 23, 2012·Clinical Cardiology·Baskar SekarSteven M Shaw
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Graziano Riccioni
Jan 23, 2013·International Journal of Cardiology·María Ángeles CastelFélix Pérez-Villa
May 15, 2013·International Journal of Cardiology·Finn Gustafsson
May 10, 2017·Clinical Transplantation·Sara VarnadoEugenia Raichlin
Nov 4, 2017·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Rasmus RiviniusAndreas O Doesch
Jun 24, 2020·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Rasmus RiviniusPhilipp Ehlermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.